22 May 2013
Keywords: AstraZeneca, Arimidex, Breast cancer, Patient program, USA
Article | 16 February 2012
Anglo-Swedish drug major AstraZeneca (LSE: AZN) has launched what it says is its first-ever direct-to-patient program offering those with a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
16 February 2012
21 May 2013
© 2013 thepharmaletter.com